It's been hard to miss the buzz around a new class of obesity medications , but one big drawback to these therapies is that they require a weekly injection. Enter biotech startup Structure Therapeutics , which is hoping to change that regimen with oral GLP-1 formulations for obesity and type 2 diabetes treatment. Structure went public earlier this month, raising $161 million in an upsized IPO.
mountain Shares have pulled back since the stock debuted earlier this month. "GSBR-1290 could help address a significant portion of patients who do not want injectable therapy or have limited access, given the oral route of administration," Seigerman wrote in a research note Tuesday. He rates the stock an outperform and has a $40 price target on it, which implies a 67% return from Monday's close.
If only there were some other way to lose weight rather than to rely on drugs.
This article title tells you everything you need to know about why they allow us to eat poison every day here in America. Big Pharma needs a revamping.